Loading
A phase 1/2 trial of Amivantamab and Olomorasib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07227025 by Janssen Research & Development, LLC, with 60 participants planned, started 2026-03-03 and due to reach its primary completion in 2028-11-30. Interventions recorded: Amivantamab and Olomorasib.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Olomorasib, KRAS & RAS inhibitors, Non-small-cell lung cancer and the tag pipeline.